Skip to main content
Signal8
Launch Terminal

Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc.

NASDAQ:CGEMHealthcare
-2.72%$15.03
AH$15.03+0.00%vs close
Mkt Cap$967.25M
Float53.54M
O/S64.35M
Vol
$ Vol
RVOL
Inst Own-
SI14.3%
Earnings
Dilution
Cullinan Therapeutics, Inc. logoNASDAQ:CGEM$15.03-2.72%
Upcoming Catalysts
  • zipalertinibPDUFA
    relapsed EGFR ex20ins NSCLC
    Cash runway at this date: 17mo
    Feb 27, 2027in 117 days8-K
Phase Distribution
12 lead-sponsored trials·7 active·0 completed
Phase 18
Phase 1/24

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 1/2
    Terminated

    Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

    VK-2019

    Nasopharyngeal Carcinoma, Nasopharyngeal Cancer

    Enrollment
    14
    Start
    Apr 2019
    Primary Completion
    Jun 2020
    Completion
    Aug 2020
    NCT03682055
  • Phase 1/2
    Active, not recruiting

    A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

    CLN-081

    Non Small Cell Lung Cancer, EGFR Exon 20 Mutation

    Enrollment
    284
    Start
    Oct 2019
    Primary Completion
    Oct 2025
    Completion
    Mar 2028est.
    NCT04036682
  • Phase 1/2
    Recruiting

    CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    CLN-049

    Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) +1

    Enrollment
    275
    Start
    Nov 2021
    Primary Completion
    Dec 2029est.
    Completion
    Dec 2029est.
    NCT05143996
  • Phase 1/2
    Not yet recruiting

    A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

    Velinotamig specified dose on specified days.

    Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)

    Enrollment
    72
    Start
    Dec 2026est.
    Primary Completion
    Jan 2029est.
    Completion
    Jan 2031est.
    NCT07738822
  • Phase 1
    Active, not recruiting

    A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

    CLN-619, Pembrolizumab

    Advanced Solid Tumor, NSCLC

    Enrollment
    440
    Start
    Oct 2021
    Primary Completion
    Mar 2026est.
    Completion
    Jun 2026est.
    NCT05117476
  • Phase 1
    Terminated

    A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

    CLN-978

    NHL, NHL, Relapsed, Adult

    Enrollment
    3
    Start
    May 2023
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT05879744
  • Phase 1
    Terminated

    CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

    CLN-617, Pembrolizumab

    Advanced Solid Tumor

    Enrollment
    23
    Start
    Dec 2023
    Primary Completion
    Jun 2026
    Completion
    Jun 2026
    NCT06035744
  • Phase 1
    Active, not recruiting

    A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

    CLN-619

    Multiple Myeloma

    Enrollment
    30
    Start
    Sep 2024
    Primary Completion
    Sep 2026est.
    Completion
    Mar 2027est.
    NCT06381141
  • Phase 1
    Recruiting

    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

    CLN-978

    SLE, SLE (Systemic Lupus)

    Enrollment
    24
    Start
    Jan 2025
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2027est.
    NCT06613360
  • Phase 1
    Recruiting

    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

    CLN-978

    Rheumatoid Arthritis (RA

    Enrollment
    37
    Start
    May 2025
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2028est.
    NCT06994143
  • Phase 1
    Recruiting

    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

    CLN-978

    Sjögren, Sjogren Disease +1

    Enrollment
    36
    Start
    Oct 2025
    Primary Completion
    Mar 2028est.
    Completion
    Mar 2029est.
    NCT07041099
  • Phase 1
    Not yet recruiting

    A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

    CLN-049, Azacitidine

    AML (Acute Myeloid Leukemia)

    Enrollment
    90
    Start
    Oct 2026est.
    Primary Completion
    Sep 2027est.
    Completion
    Aug 2030est.
    NCT07722767
Search ClinicalTrials.gov for “Cullinan Therapeutics”